



1647

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/800,103	
	Filing Date	March 6, 2001	
	First Named Inventor	Donoho, Gregory	
	Group Art Unit	1647	
	Examiner Name	R. Landsman	
Total Number of Pages in This Submission	8	Attorney Docket Number	LEX-0143-USA

RECEIVED
JUL 9 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Response (Restriction) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> To Convert a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request of Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communications to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communications to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): return postcard
Remarks		 24231 PATENT TRADEMARK OFFICE

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Lance K. Ishimoto, Reg. No. 41,866 Lexicon Genetics Incorporated
Signature	 Peter G. Seferian Reg No 40162
Date	June 26, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on this date: June 26, 2002			
Typed or printed name	Nancy Stacey		
Signature		Date	June 26, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JUL 9 2002

RECEIVED

#10k
NB
07/10/02

Applicant(s): Donoho et al.

Application No.: 09/800,103

Filed: March 6, 2001

Title: Novel Human Transporter Proteins
and Polynucleotides Encoding the
Same

Group Art Unit: 1647

Examiner: R. Landsman

Attorney Docket No.: LEX-0143-USA

**AMENDMENT; RESPONSE TO RESTRICTION AND
ELECTION REQUIREMENTS DATED MAY 30, 2002**

Commissioner for Patents
Washington, D.C. 20231

Sir:

The Examiner is respectfully requested to enter the following amendments. A response to the Restriction and Election Requirement dated May 30, 2002 (Paper No. 9) is also included herewith, and the Examiner is respectfully requested to consider the remarks therein

AMENDMENT

In the claims:

Please cancel claims 4-12, entirely without prejudice and without disclaimer, as drawn to non-elected inventions.

Please amend claim 2 so that the text of the amended claim reads as follows:

2. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence that:

- a. *See B3*
- (a) encodes the amino acid sequence of SEQ ID NO:2; and
 - (b) hybridizes under highly stringent conditions to the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

Please add new claims 13 and 14 as follows:

a² 1. -13.(New) A recombinant expression vector comprising the isolated nucleic acid molecule of claim

Q2
Cord

14. (New) A host cell comprising the recombinant expression vector of claim 13.--

RESPONSE

I. Restriction Requirement

The Examiner has determined that the original claims are directed to eight separate and distinct inventions under 35 U.S.C. § 121, as follows:

- Group I: Claims 1-3, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:1, or encoding SEQ ID NO:2, classified in class 536, subclass 23.5.
- Group II: Claim 4, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:11, or encoding SEQ ID NO:12, classified in class 536, subclass 23.5.
- Group III: Claim 5, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:37, classified in class 536, subclass 23.5.
- Group IV: Claim 6, said to be drawn to an isolated oligopeptide comprising at least 12 amino acids of SEQ ID NO:38, classified in class 530, subclass 300.
- Group V: Claims 7-9, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:13, or encoding SEQ ID NO:14, classified in class 536, subclass 23.5.
- Group VI: Claim 10, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:23, or encoding SEQ ID NO:24, classified in class 536, subclass 23.5.
- Group VII: Claim 11, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:25, classified in class 536, subclass 23.5.
- Group VIII: Claim 12, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:26, classified in class 536, subclass 23.5.

II. Response to Restriction and Election Requirement

In response to the Restriction Requirement mailed May 28, 2002 (Paper No. 9), and in compliance with 37 CFR 1.1.43, Applicants elect without traverse to prosecute the claims of Group I comprising Claims 1-3, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:1,